Does dizocilpine (MK-801) inhibit the development of morphine-induced behavioural sensitization in rats?

Life Sciences

Volumn 61, Issue 26, 1997, Pages

  Vanderschuren, Louk J M J ^a   Schoffelmeer, Anton N M ^a   De Vries, Taco J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amphetamine; Behavioral sentization; Dizocilpine; Locomotor sensitization; Morphine; NMDA receptors

Indexed keywords

DEXAMPHETAMINE; DIZOCILPINE; DIZOCILPINE MALEATE; MORPHINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG CROSS REACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; RAT; SENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DRUG INTERACTIONS; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MORPHINE; MOTOR ACTIVITY; NARCOTICS; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0345642508     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01031-X     Document Type: Article

References (20)

1. ROBINSON T.E., BERRIDGE K.C. Brain Res. Rev. 18:1993;247-291.
2. KARLER R., CHAUDHRY I.A., CALDER L.D., TURKANIS S.A. Brain Res. 537:1990;76-82.
3. WOLF M.E., JEZIORSKI M. Brain Res. 613:1993;291-294.
4. JEZIORSKI M., WHITE F.J., WOLF M.E. Synapse. 16:1994;137-147.
5. TZSCHENTKE T.M., SCHMIDT W.J. Behav. Pharmacol. 7:1996;169-184.
6. TJON G.H.K., DE VRIES T.J., RONKEN E., HOGENBOOM F., WARDEH G., MULDER A.H., SCHOFFELMEER A.N.M. Eur. J. Pharmacol. 252:1994;205-212.
7. TJON G.H.K., DE VRIES T.J., NESTBY P., WARDEH G., MULDER A.H., SCHOFFELMEER A.N.M. Eur. J. Pharmacol. 283:1995;169-176.
8. NESTBY P., VANDERSCHUREN L.J.M.J., DE VRIES T.J., HOGENBOOM F., WARDEH G., MULDER A.H., SCHOFFELMEER A.N.M. Psychopharmacology. 133:1997;69-76.
9. VANDERSCHUREN L.J.M.J., TJON G.H.K., NESTBY P., MULDER A.H., SCHOFFELMEER A.N.M., DE VRIES T.J. Psychopharmacology. 131:1997;115-122.
10. FOUTZ A.S., CHAMPAGNAT J., DENAVIT-SAUBIÉ Eur. J. Pharmacol. 154:1988;179-184.
11. TRUJILLO K.A., AKIL H. Science. 251:1991;85-87.
12. TRUJILLO K.A., AKIL H. Pharmacol. Biochem. Behav. 38:1991;673-675.
13. TZSCHENTKE T.M., SCHMIDT W.J. Eur. J. Pharmacol. 295:1996;137-146.
14. WOLF M.E., KHANSA M.R. Brain Res. 562:1991;164-168.
15. WOLF M.E., WHITE F.J., HU X-T Behav. Pharmacol. 4:1993;429-442.
16. TOLLIVER B.K., HO L.B., REID M.S., BERGER S.P. Psychopharmacology. 126:1996;191-198.
17. CAREY R.J., DAI H.L., KROST M., HUSTON J.P. Pharmacol. Biochem. Behav. 51:1995;901-908.
18. WILLINS D.L., NARAYANAN S., WALLACE L.J., URETSKY N.J. Pharmacol. Biochem. Behav. 46:1993;881-887.
19. WOLF M.E., WHITE F.J., HU X.T. J. Neurosci. 14:1994;1735-1745.
20. F.J. WHITE, X-T. HU, D.J. HENRY and X-F. ZHANG, The neurobiology of cocaine, R.P. Hammer, Jr. (Ed), 99-119, CRC Press, Boca Raton (1995).